KURAHealthcare · BiotechnologyThe 16 Wall Street analysts covering Kura Oncology, Inc. hold a median 12-month price target of $28 — +166.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 8 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Kura Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.
Growth (21): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on KURA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +166.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 Oct 2026 | JP Morgan | Initiates | Overweight | $30 |
| 24 Aug 2026 | Citizens | Reiterates | Market Outperform | — |
| 24 Aug 2026 | Citizens | Reiterates | Market Outperform | $24 |
| 13 Aug 2026 | Wedbush | Maintains | Outperform | — |
| 13 Aug 2026 | Wedbush | Maintains | Outperform | $36 → $38 |
| 28 July 2026 | Wedbush | Reiterates | Outperform | $36 |
| 28 July 2026 | Wedbush | Reiterates | Outperform | — |
| 15 June 2026 | Citizens | Reiterates | Market Outperform | $24 |
| 15 June 2026 | Citizens | Reiterates | Market Outperform | — |
| 14 Apr 2026 | Lake Street | Initiates | Buy | — |
| 24 Mar 2026 | Mizuho | Maintains | Outperform | — |
| 13 Mar 2026 | UBS | Maintains | Buy | — |
| 6 Mar 2026 | Wedbush | Maintains | Outperform | — |
| 13 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Jan 2026 | Leerink Partners | Maintains | Outperform | — |
| 24 Nov 2025 | Barclays | Maintains | Overweight | — |
| 14 Nov 2025 | UBS | Maintains | Buy | — |
| 14 Nov 2025 | Wedbush | Maintains | Outperform | — |
| 20 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Oct 2025 | JMP Securities | Reiterates | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KURA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Kura Oncology, Inc. returned +4.4% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 88% of US stocks
Cheaper than 13% of US stocks
Cheaper than 5% of US stocks
Cheaper than 70% of US stocks
Higher than 81% of US stocks
Higher than 69% of US stocks
Higher than 99% of US stocks
Higher than 9% of US stocks
Higher than 99% of US stocks
Higher than 9% of US stocks
Higher than 13% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Kura Oncology, Inc. has a market value of $936.8M and an enterprise value of $442.2M.
Revenue in the twelve months to 30 June 2026: $77.2M. The latest quarter grew 36.5% year on year.
Net income over the same four quarters: −$296.8M, a −384.3% net margin.
Diluted earnings per share, trailing twelve months: $−3.37.
Free cash flow in the twelve months to 30 June 2026: −$117.4M.
Trailing P/E: −3.3×; forward P/E: −4.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Kura Oncology, Inc. employs 260 people — $297K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Kura Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Caspian Therapeutics and Kura Oncology will host an investor webcast on October 13, 2026, at 4:30 p.m. ET (1:30 p.m. PT), highlighting Caspian's launch and preclinical data for KO-7246 in diabetes.
Why it matters — KURA watchers may be interested in the planned presentation of preclinical data on the company's KO-7246 program.
Kura Oncology announced that on October 1, 2026, its Compensation Committee granted inducement awards of nonstatutory stock options to purchase 128,250 shares of common stock to nine new employees under the company's 2023 Inducement Option Plan, as amended, in accordance with Nasdaq Listing Rule 5635(c)(4).
Why it matters — A KURA watcher would care because the inducement grants signal the company is hiring and compensating new employees with stock options, which may have modest dilutive implications and reflect workforce expansion.
Caspian Therapeutics unveiled KO-7246 at the EASD as a potential best-in-class menin inhibitor for diabetes, reporting that it regenerated functional β-cell mass and produced durable glycemic control in Type 1 and Type 2 diabetes models.
Why it matters — KO-7246 is a menin inhibitor developed by Kura Oncology's collaborator, and its diabetes-focused research could broaden the clinical potential of the menin-inhibitor platform beyond oncology.
Kura Oncology presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha.
Why it matters — The presentation gives KURA watchers an opportunity to hear company executives discuss their business and pipeline directly with investors.
Kura Oncology launched Caspian Therapeutics, a separately financed company established to advance small-molecule menin inhibitors for diabetes and cardiometabolic diseases. The launch is backed by $50 million in financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly, and others, and is designed to advance the lead candidate KO-7246 through initial clinical proof of concept.
Why it matters — A KURA watcher would care because Kura retains a substantial ownership stake in Caspian (approximately half of the company on a fully diluted basis) while the separately financed subsidiary dedicates capital and leadership to its diabetes program, allowing Kura to remain focused on oncology and potentially benefit from a new therapeutic avenue without diverting its core resources.
The 16 Wall Street analysts covering Kura Oncology, Inc. have a median 12-month price target of $28, with estimates ranging from $15 to $76. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering Kura Oncology, Inc., 15 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kura Oncology, Inc. 80 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Kura Oncology, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies +166.2% from the last close, and Ticker Nerd's factor model ranks Kura Oncology, Inc. 80 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Kura Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KURA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $76 over the next 12 months.
Kura Oncology, Inc. returned +4.4% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of cancer.
The most recent item we track (GlobeNewsWire, 7 Oct 2026): "Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in Diabetes". Caspian Therapeutics and Kura Oncology will host an investor webcast on October 13, 2026, at 4:30 p.m. ET (1:30 p.m. PT), highlighting Caspian's launch and preclinical data for KO-7246 in diabetes.
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of cancer. Kura Oncology’s current portfolio centers on precision oncology programs designed to target specific molecular drivers of disease, with an emphasis on hematologic malignancies and selected solid tumors. Its pipeline includes small-molecule drug candidates such as ziftomenib, tipifarnib, and KO-2806, which are being evaluated in clinical development for genetically defined patient populations. The company’s work combines drug discovery, biomarker-driven research, and clinical testing to support targeted treatment approaches in oncology. Based in San Diego, California, Kura Oncology operates as a focused biotechnology company within the broader cancer therapeutics market, contributing to the development of specialized therapies for patients with high unmet medical need.
CEO Dr. Troy Edward Wilson J.D., Ph.D. · 260 employees · United States · https://kuraoncology.com
